Neoadjuvant Chemotherapy Followed by Surgery-A Promising Strategy to Reduce Morbidity in Locally Advanced Tongue Cancer.

IF 2.2 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2025-09-09 DOI:10.1002/hed.70035

G A Deshpande, S Rai, A Singh, V Gautam, S Goyal, R Saha, S Tandon, M Gairola, S Upadhya, M Agarwal

{"title":"Neoadjuvant Chemotherapy Followed by Surgery-A Promising Strategy to Reduce Morbidity in Locally Advanced Tongue Cancer.","authors":"G A Deshpande, S Rai, A Singh, V Gautam, S Goyal, R Saha, S Tandon, M Gairola, S Upadhya, M Agarwal","doi":"10.1002/hed.70035","DOIUrl":null,"url":null,"abstract":"Background: Though neoadjuvant chemotherapy (NACT) has not improved survival in oral cancers, its role in tongue cancer remains uncertain.Methods: This was a retrospective study of patients with locally advanced oral tongue cancer (Stage III-IVB) to assess response rates, mandibular preservation, and surgical extent post-NACT, along with recurrence and survival outcomes.Results: Of 72 patients, 20 (27.8%) received NACT, while 52 (72.2%) underwent upfront surgery. In the NACT group, 15 (75%) received TPF chemotherapy for a median of 3 cycles. One patient (5%) had a complete response, and 13 (65%) had a partial response. The clinical benefit rate was 85%. Tumor downstaging occurred in 14 (70%) patients, with 6 (42.9%) requiring less extensive surgery. The mandibular preservation rate was 75%. The pathological complete response was 10%. Local and distant control rates, disease-free survival, and overall survival were comparable.Conclusion: Despite its retrospective design and small sample size, this study suggests that NACT can downstage tumors, improve response rates, and enable less extensive surgery in locally advanced tongue cancer.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.70035","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Though neoadjuvant chemotherapy (NACT) has not improved survival in oral cancers, its role in tongue cancer remains uncertain.

Methods: This was a retrospective study of patients with locally advanced oral tongue cancer (Stage III-IVB) to assess response rates, mandibular preservation, and surgical extent post-NACT, along with recurrence and survival outcomes.

Results: Of 72 patients, 20 (27.8%) received NACT, while 52 (72.2%) underwent upfront surgery. In the NACT group, 15 (75%) received TPF chemotherapy for a median of 3 cycles. One patient (5%) had a complete response, and 13 (65%) had a partial response. The clinical benefit rate was 85%. Tumor downstaging occurred in 14 (70%) patients, with 6 (42.9%) requiring less extensive surgery. The mandibular preservation rate was 75%. The pathological complete response was 10%. Local and distant control rates, disease-free survival, and overall survival were comparable.

Conclusion: Despite its retrospective design and small sample size, this study suggests that NACT can downstage tumors, improve response rates, and enable less extensive surgery in locally advanced tongue cancer.

查看原文本刊更多论文

手术后新辅助化疗-降低局部晚期舌癌发病率的一种有希望的策略。

背景：虽然新辅助化疗（NACT）没有提高口腔癌患者的生存率，但其在舌癌中的作用仍不确定。方法：这是一项对局部晚期口腔癌（III-IVB期）患者的回顾性研究，以评估nact后的反应率、下颌保存和手术范围，以及复发和生存结果。结果：72例患者中，20例（27.8%）接受了NACT治疗，52例（72.2%）接受了术前手术。在NACT组中，15例（75%）接受TPF化疗，中位数为3个周期。1例（5%）患者完全缓解，13例（65%）患者部分缓解。临床获益率为85%。14例（70%）患者出现肿瘤分期下降，6例（42.9%）患者需要较少的手术。下颌骨保存率为75%。病理完全缓解率为10%。本地和远程控制率、无病生存率和总生存率具有可比性。结论：尽管其回顾性设计和小样本量，该研究表明NACT可以降低肿瘤的分期，提高反应率，并使局部晚期舌癌的手术范围更小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.